Development of a dispersable paediatric pyrazinamide tablet: A model compounding formulary in resource limited primary healthcare settings

Abstract

Tuberculosis (TB) is a global and public health issue. TB burden is high in developing countries like Nigeria. Paediatric TB patient population is high and therapy is challenged because commonly tablet formulations are presented as adult doses which necessitates breakages or splitting into either halves, one-thirds or quarters as equivalent paediatric doses. However, this often results in
dose inaccuracies (sub-optimal and overdosing).

The End TB-Strategy of WHO targets a substantial reduction in paediatric TB by 2035. Proactive measures such as the development of paediatric solid dosage formulations are needed to attain this set goal Compounding of cost-effective pharmaceuticals is an
essential component in primary healthcare.